Inhibition of the glycine transporter GlyT-1 potentiates the effect of risperidone, but not clozapine, on glutamatergic transmission in the rat medial prefrontal cortex

Synapse

Volumn 60, Issue 2, 2006, Pages 102-108

  Konradsson, Åsa ^a   Marcus, Monica M ^a   Hertel, Peter ^b   Svensson, Torgny H ^a   Jardemark, Kent E ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b H LUNDBECK A S   (Denmark)

Author keywords

Clozapine; Medial prefrontal cortex; NFPS; NMDA; Risperidone

Indexed keywords

CLOZAPINE; GLUTAMIC ACID; GLYCINE; GLYCINE TRANSPORTER 1; GLYCINE TRANSPORTER 1 INHIBITOR; N METHYL DEXTRO ASPARTIC ACID; PROTEIN INHIBITOR; RISPERIDONE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; INTRACELLULAR RECORDING; MALE; NEUROTRANSMISSION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RAT;

ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; CLOZAPINE; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; EXCITATORY POSTSYNAPTIC POTENTIALS; GABA ANTAGONISTS; GLUTAMIC ACID; GLYCINE; GLYCINE PLASMA MEMBRANE TRANSPORT PROTEINS; MALE; ORGAN CULTURE TECHNIQUES; PREFRONTAL CORTEX; PYRAMIDAL CELLS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; RISPERIDONE; SARCOSINE; SYNAPTIC TRANSMISSION;

EID: 33745026642     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20286     Document Type: Article

References (40)

1. Akbarian S, Sucher NJ, Bradley D, Tafazzoli A, Trinh D, Hetrick WP, Potkin SG, Sandman CA, Bunney WE Jr., Jones EG. 1996. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci 16:19-30.
2. 2A receptor antagonist and a potential antipsychotic drug, facilitates N-methyl-D-aspartate-receptor mediated neurotransmission in the rat medial prefrontal cortical neurons in vitro. Neuropsychopharmacology 18:197-209.
3. Arvanov VL, Liang X, Schwartz J, Grossman S, Wang RY. 1997. Clozapine and haloperidol modulate N-methyl-D-aspartate- and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J Pharmacol Exp Ther 283:226-234.
4. Borowsky B, Mezey E, Hoffman BJ. 1993. Two glycine transporter variants with distinct localization in the CNS and peripheral tissues are encoded by a common gene. Neuron 10:851-863.
5. Chen L, Yang CR. 2002. Interaction of dopamine D1 and NMDA receptors mediates acute clozapine potentiation of glutamate EPSPs in rat prefrontal cortex. J Neurophysiol 87:2324-2336.
6. Chen L, Muhlhauser M, Yang CR. 2003. Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo. J Neurophysiol 89:691-703.
7. Deutsch SI, Mastropaolo J, Schwartz BL, Rosse RB, Morihisa JM. 1989. A "glutamatergic hypothesis" of schizophrenia. Rationale for pharmacotherapy with glycine. Clin Neuropharmacol 12:1-13.
8. Dracheva S, Marras SA, Elhakem SL, Kramer FR, Davis KL, Haroutunian V. 2001. N-methyl-D-aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia. Am J Psychiatry 158:1400-1410.
9. Emmett MR, Mick SJ, Cler JA, Rao TS, Iyengar S, Wood PL. 1991. Actions of D-cycloserine at the N-methyl-D-aspartate-associated glycine receptor site in vivo. Neuropharmacology 30:1167-1171.
10. Evins AE, Fitzgerald SM, Wine L, Rosselli R, Goff DC. 2000. Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry 157:826-828.
11. Evins AE, Amico E, Posever TA, Toker R, Goff DC. 2002. D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophr Res 56:19-23.
12. Gao XM, Sakai K, Roberts RC, Conley RR, Dean B, Tamminga CA. 2000. Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: Effects of schizophrenia. Am J Psychiatry 157:1141-1149.
13. Goff DC, Henderson DC, Evins AE, Amico EA. 1999a. A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry 45:512-514.
14. Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Shoenfeld DA. 1999b. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 56:21-27.
15. Goldman-Rakic PS, Selemon LD. 1997. Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr Bull 23:437-458.
16. Harrison PJ, Owen MJ. 2003. Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet 361:417-419.
17. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Horowitz A, Kelly D. 1996. Double blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry 169:610-617.
18. Heresco-Levy U, Ermilov M, Lichtenberg P, Bar G, Javitt DC. 2004. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol Psychiatry 55:165-171.
19. Heresco-Levy U, Javitt DC, Ebstein R, Vass A, Lichtenberg P, Bar G, Catinari S, Ermilov M. 2005. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry 57:577-585.
20. Jardemark KE, Ai J, Ninan I, Wang RY. 2001. Biphasic modulation of NMDA-induced responses in pyramidal cells of the medial prefrontal cortex by Y-931, a potential atypical antipsychotic drug. Synapse 41:294-300.
21. Javitt DC, Zukin SR. 1991. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-1308.
22. Javitt DC, Duncan L, Balla A, Sershen H. 2005. Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: Implications for mechanisms of action. Mol Psychiatry 10:275-287.
23. Johnson JW, Ascher P. 1987. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 325:529-531.
24. Konradsson A, Marcus MM, Hertel P, Svensson TH, Jardemark KE. 2005. Inhibition of the glycine transporter (GlyT1) potentiates the effect of risperidone, but not clozapine, on glutamatergic transmission in the rat medial prefrontal cortex. SCNP 46th Annual Meeting, April 27-30, 2005 (Poster P-33).
25. 2/3 receptor blockade enhances cortical glutamatergic transmission and reverses cognitive impairment in the rat. Int J Neuropsychopharmacol 8:315-327.
26. Maurer TS, Debartolo DB, Tess DA, Scott DO. 2005. Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug Metab Dispos 33:175-181.
27. Meador-Woodruff JH, Healy DJ. 2000. Glutamate receptor expression in schizophrenic brain. Brain Res Brain Res Rev 31:288-294.
28. Mueller HT, Meador-Woodruff JH. 2004. NR3A NMDA receptor subunit mRNA expression in schizophrenia, depression and bipolar disorder. Schizophr Res 71:361-370.
29. Ninan I, Wang RY. 2003. Modulation of the ability of clozapine to facilitate NMDA- and electrically evoked responses in pyramidal cells of the rat medial prefrontal cortex by dopamine: Pharmacological evidence. Eur J Neurosci 17:1306-1312.
30. Ninan I, Jardemark KE, Wang RY. 2003. Differential effects of atypical and typical antipsychotic drugs on N-methyl-D-aspartate- and electrically evoked responses in the pyramidal cells of the rat medial prefrontal cortex. Synapse 48:66-79.
31. Olney JW, Farber NB. 1995. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52:998-1007.
32. Potkin SG, Jin Y, Bunney BG, Costa J, Gulasekaram B. 1999. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. Am J Psychiatry 156:145-147.
33. Schwieler L, Engberg G, Erhardt S. 2004. Clozapine modulates midbrain dopamine neuron firing via interaction with the NMDA receptor complex. Synapse 52:114-122.
34. Smith KE, Borden LA, Hartig PR, Branchek T, Weinshank RL. 1992. Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors. Neuron 8:927-935.
35. Spina E, Avenoso A, Facciola G, Scordo MG, Ancione M, Madia AG, Ventimiglia A, Perucca E. 2000. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology (Berl) 148:83-89.
36. Spina E, Avenoso A, Facciola G, Salemi M, Scordo MG, Ancione M, Madia AG, Perucca E. 2001. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology (Berl) 153:238-243.
37. Svensson TH. 2000. Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs. Brain Res Brain Res Rev 31:320-329.
38. Tsai G, Lane HY, Yang P, Chong MY, Lange N. 2004. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 55:452-456.
39. Tsai GE, Yang P, Chung LC, Tsai IC, Tsai CW, Coyle JT. 1999. D-serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry 156:1822-1825.
40. Williams JB, Mallorga PJ, Jeffrey Conn P, Pettibone DJ, Sur C. 2004. Effects of typical and atypical antipsychotics on human glycine transporters. Schizophr Res 71:103-112.